655 related articles for article (PubMed ID: 11920888)
21. Does low molecular weight heparin influence the triple test result in pregnant women with thrombophilia?
Wiener Y; Frank M; Neeman O; Kurzweil Y; Bar J; Maymon R
Isr Med Assoc J; 2012 Apr; 14(4):247-50. PubMed ID: 22675844
[TBL] [Abstract][Full Text] [Related]
22. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
[TBL] [Abstract][Full Text] [Related]
23. [Screening for Down syndrome using triple marker testing in the second trimester of pregnancy].
Lesin J; Skrablin S; Durić K; Suchanek E; Muzinić D; Kalafatić D; Kuvacić I; Zlopasa G; Plavec A
Lijec Vjesn; 2003; 125(3-4):55-60. PubMed ID: 12899094
[TBL] [Abstract][Full Text] [Related]
24. Screening of maternal serum for fetal Down's syndrome in the first trimester.
Haddow JE; Palomaki GE; Knight GJ; Williams J; Miller WA; Johnson A
N Engl J Med; 1998 Apr; 338(14):955-61. PubMed ID: 9521983
[TBL] [Abstract][Full Text] [Related]
25. Second-trimester maternal serum analyte levels associated with fetal trisomy 13.
Saller DN; Canick JA; Blitzer MG; Palomaki GE; Schwartz S; Blakemore KJ; Haddow JE
Prenat Diagn; 1999 Sep; 19(9):813-6. PubMed ID: 10521837
[TBL] [Abstract][Full Text] [Related]
26. Choroid plexus cysts: Is biochemical testing a valuable adjunct to targeted ultrasonography?
Sullivan A; Giudice T; Vavelidis F; Thiagarajah S
Am J Obstet Gynecol; 1999 Aug; 181(2):260-5. PubMed ID: 10454666
[TBL] [Abstract][Full Text] [Related]
27. The detection of non-immune hydrops through second-trimester maternal serum screening.
Saller DN; Canick JA; Oyer CE
Prenat Diagn; 1996 May; 16(5):431-5. PubMed ID: 8844001
[TBL] [Abstract][Full Text] [Related]
28. 'Dual positivity' for neural tube defects and down syndrome at maternal serum screening: gestational outcome.
Zanini R; Tarantini M; Cerri V; Jacobello C; Bellotti D; Lancetti S; Scalchi S; Groli C; Bianchi UA
Fetal Diagn Ther; 1998; 13(2):106-10. PubMed ID: 9650657
[TBL] [Abstract][Full Text] [Related]
29. Ultrasonographic markers for chromosomal abnormalities in women with negative nuchal translucency and second trimester maternal serum biochemistry.
Verdin SM; Whitlow BJ; Lazanakis M; Kadir RA; Chatzipapas I; Economides DL
Ultrasound Obstet Gynecol; 2000 Oct; 16(5):402-6. PubMed ID: 11169322
[TBL] [Abstract][Full Text] [Related]
30. Multiple marker screening test: identification of fetal cystic hygroma, hydrops, and sex chromosome aneuploidy.
Wenstrom KD; Boots LR; Cosper PC
J Matern Fetal Med; 1996; 5(1):31-5. PubMed ID: 8796763
[TBL] [Abstract][Full Text] [Related]
31. [Diagnostic methods for fetal malformations in the first half of pregnancy].
Sieroszewski P; Suzin J; Baś-Budecka E
Ginekol Pol; 2003 Oct; 74(10):1276-83. PubMed ID: 14669430
[TBL] [Abstract][Full Text] [Related]
32. Appropriate biochemical parameters in first-trimester screening for Down syndrome.
Cuckle HS; van Lith JM
Prenat Diagn; 1999 Jun; 19(6):505-12. PubMed ID: 10416963
[TBL] [Abstract][Full Text] [Related]
33. Second trimester maternal serum ADAM12 levels in Down's syndrome pregnancies.
Donalson K; Turner S; Wastell H; Cuckle H
Prenat Diagn; 2008 Oct; 28(10):904-7. PubMed ID: 18785180
[TBL] [Abstract][Full Text] [Related]
34. Nuchal translucence incorporated into a one-stage multifactorial screening model for Down syndrome prediction at second-trimester pregnancy.
Hung JH; Fu CY; Yuan CC; Chen CL; Yang ML; Shu LP; Wu CC
Ultrasound Med Biol; 2003 Dec; 29(12):1667-74. PubMed ID: 14698332
[TBL] [Abstract][Full Text] [Related]
35. Detection of maternal serum hCG glycoform variants in the second trimester of pregnancies affected by Down syndrome using a lectin immunoassay.
Talbot JA; Spencer K; Abushoufa RA
Prenat Diagn; 2003 Jan; 23(1):1-5. PubMed ID: 12533803
[TBL] [Abstract][Full Text] [Related]
36. Normal nuchal thickness in the midtrimester indicates reduced risk of Down syndrome in pregnancies with abnormal triple-screen results.
Bahado-Singh RO; Goldstein I; Uerpairojkit B; Copel JA; Mahoney MJ; Baumgarten A
Am J Obstet Gynecol; 1995 Oct; 173(4):1106-10. PubMed ID: 7485301
[TBL] [Abstract][Full Text] [Related]
37. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
38. Serum triple-marker screening in in vitro fertilization and naturally conceived pregnancies.
Frishman GN; Canick JA; Hogan JW; Hackett RJ; Kellner LH; Saller DN
Obstet Gynecol; 1997 Jul; 90(1):98-101. PubMed ID: 9207822
[TBL] [Abstract][Full Text] [Related]
39. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome.
Spencer K; Crossley JA; Aitken DA; Nix AB; Dunstan FD; Williams K
Ann Clin Biochem; 2003 May; 40(Pt 3):219-31. PubMed ID: 12803832
[TBL] [Abstract][Full Text] [Related]
40. Analysis of maternal serum alpha-fetoprotein and free beta human chorionic gonadotrophin in the first trimester: implications for Down's syndrome screening.
Berry E; Aitken DA; Crossley JA; Macri JN; Connor JM
Prenat Diagn; 1995 Jun; 15(6):555-65. PubMed ID: 7544898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
